StreetAlpha.app
Home › Stocks › TENX

Tenax Therapeutics, Inc. (TENX)

Healthcare
$1.42
▼ −4.05%
LAST CLOSE · NOV 17

Tenax Therapeutics develops oral levosimendan, a drug candidate for pulmonary hypertension in heart failure with preserved ejection fraction. It last closed at $1.42 on Nov 17, down 4.05% on the day.

AI Auto Pilots
Is TENX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$65.8M
EPS (diluted)
−$1.39
Valuation
Market cap
$64.7M
45.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$113.7M
At Sep 30
Shareholder equity
$108.7M
Shares outstanding
45.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $0$0FY2025

From TENX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated TENX in the past 90 days.
Average 12-month target
No price targets on TENX in the past 90 days.
Latest rating changes
Chardan CapitalDowngrade
Aug 11Hold$27 → $5
Canaccord GenuityMaintained
Aug 11Buy$4
GuggenheimTarget lowered
Aug 11Buy$40 → $4
Evercore ISI GroupDowngrade
Aug 11Hold$39 → $5
Canaccord GenuityInitiated
Jul 28Buy$35
DateFirmActionRatingPrice target
Aug 11Chardan CapitalDowngradeHold$27 → $5
Aug 11Canaccord GenuityMaintainedBuy$4
Aug 11GuggenheimTarget loweredBuy$40 → $4
Aug 11Evercore ISI GroupDowngradeHold$39 → $5
Jul 28Canaccord GenuityInitiatedBuy$35
Loading…

Technical Analysis

TENX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 20% below its 20 day and 25% below its 50 day average. It is 554% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $1.38, and the nearest resistance the Pivot at $1.44.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.8%/day
Key levels
$19.4052 week high+1266.2%
$9.29200 day average+554.2%
$5.68100 day average+300.0%
$1.84Swing high (Oct 22)+29.6%
$1.7750 day average+24.6%
$1.7020 day average+19.7%
$1.48Pivot R1+4.2%
$1.44Pivot+1.4%
$1.42Last close
$1.38Pivot S1−2.8%
$1.36Swing low (Oct 16)−4.2%
$1.3152 week low−7.7%
Indicators
RSI (14)33.42Weak, oversold below 30Neutral
MACD-0.11Below its signal lineBearish
Stochastic8.3Near the bottom of its rangeOversold
ADX (14)20.9Weak trend
Williams %R-96.7Oversold below −80, overbought above −20Oversold
CCI (20)-209.7Oversold below −100, overbought above 100Oversold
Rate of change−22.8%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TENX

What happened before

See how TENX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TENX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TENX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TENX in the last 90 days.

Loading…

See today’s whale options flow across the market →

TENX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●66 buying vs 58 selling
  • ▲Held by funds +3.4 pts
  • ▼Funds holding -7
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding106113−6.2%
In funds' top 1004−100.0%
Held by funds70.2%66.8%+3.4 pts
New / increased30 / 3645 / 39−21.4%
Reduced / sold out21 / 3714 / 13+114.8%
Put/call ratio0.000.05−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TENX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TENX is in one of them and how their past TENX trades turned out.

TENX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TENX in an article yet. Here's the latest on the wider market.

About Tenax Therapeutics

Tenax Therapeutics is a pharmaceutical company developing drugs for cardiopulmonary conditions. Its main candidate is oral levosimendan, a drug already marketed in other countries for acute heart failure, which it is testing for pulmonary hypertension in heart failure with preserved ejection fraction. No therapy is currently approved for that condition in the United States. The company is based in Chapel Hill, North Carolina, and targets patients with this form of pulmonary hypertension.

Headquarters
Chapel Hill, NC